Date:9/4/2007

clobazam brings new hope to the children and young adults who suffer from this devastating condition." For this patient population, there is an urgent need for novel therapies that help manage the disease, said lead study investigator Joan A. Conry, M.D., Professor of Neurology and Pediatrics in the Department of Neurology at Childrens National Medical Center in Washington, D.C. We know clobazam has an internationally well established safety and efficacy profile and if the results we have seen thus far are an indication of its potential in patients with LGS in the U.S., we may finally have a treatment that will fill an important unmet need.

Clobazam is one of the key products in OVATIONs CNS development program. The company is advancing its near-term pipeline on other fronts as well. In July 2007, the company initiated a clinical trial to evaluate a novel intravenous formulation of carbamazepine, a widely used oral antiepileptic drug, in adult patients with epilepsy. The launch of another oral anticonvulsant for rare and refractory epilepsies is anticipated next year.

'/>"/>

Contact: Nikki Nelson nikki.nelson@edelman.com 312-565-2183 Edelman Public Relations Source:Eurekalert

1 GOOD

Page: 1 2
Related medicine news :

1. Genetic innovation
2. Biocon To Shift Focus On Innovation To Accelerate Growth
3. IIT Delhi To Display Its Technological Innovations In Open House
4. Patent for Seminal RNAi innovation Cleared in Australia
5. Innovation Needed In The Field Of Diagnostics: Nair
6. A young scientist recognized for biomechanics innovations
7. Blood Safety, Supply, and Innovations Addressed at Conference
8. New Innovation in Clubfoot Treatment
9. Further support for use of statins in Alzheimer’s disease
10. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
11. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered